진단용 효소 시장 규모, 점유율, 동향 분석 보고서 : 유형별, 용도별, 제품별, 최종 용도별, 지역별, 부문별 예측(2025-2030년)

Diagnostic Enzymes Market Growth & Trends:

The global diagnostic enzymes market size is expected to reach USD 7.71 billion by 2030, registering a CAGR of 7.1% from 2025 to 2030, according to a new report by Grand View Research, Inc. Growth of the diagnostic enzymes market is attributed to rising demand for the enzymes in diagnostics with wide applications in pathology. Moreover, advancements in diagnostic techniques for viral infection are anticipated to propel the market growth.

Diagnostic enzymes are widely adopted owing to the higher sensitivity and accuracy offered by enzyme activity. The enzyme activities can be earlier than clinical signs and other diagnostic indicators. Biosensors are becoming a popular potential tool for medical diagnostics, pathogen detection, and monitoring. Biosensors have gained popularity owing to the accuracy, sensitivity, selectivity, and rapid detection strategies that can be used routinely. Diagnosis of serum levels of the enzymes has been used as an indicator of the cellular damage that results in the release of the intercellular components into the bloodstream.

Viral infections of the respiratory tract are among the most common disorders in humans, and the ones caused due to the outbreak of emerging viruses, such as COVID-19, have posed a threat to public health. Therefore, detection of the viral pathogens is vital to stop the occurrence of such epidemics and prevent the unnecessary use of antibiotics. Therefore, novel diagnostic strategies have been adopted by the key players. LightMix (Roche Molecular Diagnostics, Switzerland), AccuPower (Bioneer, Korea), PowerChek (Kogene Biotech, Korea), Anyplex (Seegene, Korea), UltraFast kits (Nanobiosys, Korea), and DiaPlexQ (SolGent, Korea) are some of the commercially available RT-PCR kits for MERS-CoV RNA detection with sensitivities as high as 99.03%.

An increase in the number of diagnostic enzyme tests has led to a boost in recommendations and guidelines with a number of publications on their performance. Moreover, reimbursement pathways lack clear guidelines and systematic Health Technology Assessment (HTA). Various factors influencing payer decisions for diagnostic enzyme tests include FDA clearance, physician support & clinical guidelines, competitor coverage policies, cost/benefit analyses, results of HTAs, and employer or advocacy group demands.

Furthermore, key players operating in the market are focusing on expanding and launching products that can be used for a wide range of applications. For instance, in March 2022, Meridian Bioscience, Inc. launched two master mixes, which can be used in non-invasive liquid biopsy. The launch of such breakthrough technologies enables better analysis of the performance levels as compared to traditional qPCR from the purified nucleic acid.

Diagnostic Enzymes Market Report Highlights:

• The glucose oxidase/dehydrogenase segment accounted for the largest revenue share of 9.3% in 2024. Glucose oxidase (GOx) is in high demand primarily due to its essential role in glucose monitoring and its increasing applications in various biomedical fields.
• The lactate dehydrogenase (LDH) segment is anticipated to experience substantial growth throughout the forecast period, largely driven by the rising adoption of molecular devices for diabetes management.
• The infectious diseases segment held the largest market share of 36.0% in 2024. The widespread application of PCR technology has significantly advanced the early identification and treatment of infectious diseases.
• The oncology segment is expected to grow at a CAGR of 8.8% over the forecast period.
• The clinical enzyme segment accounted for the largest revenue share of 65.3% in 2024, largely due to the increasing application of enzymes in clinical chemistry.
• The clinical laboratories segment held the largest market share of 48.2% in 2024. The segment growth is driven by multiple factors.

Table of Contents

Chapter 1. Methodology and Scope

• 1.1. Market Segmentation and Scope
• 1.2. Segment Definitions
  • 1.2.1. Product
  • 1.2.2. Type
  • 1.2.3. Application
  • 1.2.4. End Use
  • 1.2.5. Regional Scope
  • 1.2.6. Estimates and forecasts timeline
• 1.3. Research Methodology
• 1.4. Information Procurement
  • 1.4.1. Purchased database
  • 1.4.2. GVR's internal database
  • 1.4.3. Secondary sources
  • 1.4.4. Primary research
  • 1.4.5. Details of primary research
• 1.5. Information or Data Analysis
  • 1.5.1. Data analysis models
• 1.6. Market Formulation & Validation
• 1.7. Model Details
  • 1.7.1. Commodity flow analysis (Model 1)
  • 1.7.2. Approach 1: Commodity flow approach
  • 1.7.3. Volume price analysis (Model 2)
  • 1.7.4. Approach 2: Volume price analysis
• 1.8. List of Secondary Sources
• 1.9. List of Primary Sources
• 1.10. Objectives

Chapter 2. Executive Summary

• 2.1. Market Outlook
• 2.2. Segment Outlook
• 2.3. Regional outlook
• 2.4. Competitive Insights

Chapter 3. Diagnostic Enzymes Market Variables, Trends & Scope

• 3.1. Market Lineage Outlook
  • 3.1.1. Parent Market Outlook
  • 3.1.2. Related/ancillary market outlook
• 3.2. Market Dynamics
  • 3.2.1. Market Driver Analysis
    • 3.2.1.1. Rise in the demand for enzymes in pathology
    • 3.2.1.2. Advancements in diagnostic testing of viral infection
    • 3.2.1.3. Increase in the demand for Point-of-Care testing
  • 3.2.2. Market Restraint Analysis
    • 3.2.2.1. High cost of enzyme-based diagnostic tests
    • 3.2.2.2. Regulatory & reimbursement hurdles for enzyme diagnostics
• 3.3. Diagnostic Enzymes Market Analysis Tools
  • 3.3.1. Industry Analysis - Porter's
    • 3.3.1.1. Bargaining power of suppliers
    • 3.3.1.2. Bargaining power of buyers
    • 3.3.1.3. Threat of substitutes
    • 3.3.1.4. Threat of new entrants
    • 3.3.1.5. Competitive rivalry
  • 3.3.2. PESTEL Analysis
    • 3.3.2.1. Political landscape
    • 3.3.2.2. Economic landscape
    • 3.3.2.3. Social landscape
    • 3.3.2.4. Technological landscape
    • 3.3.2.5. Environmental landscape
    • 3.3.2.6. Legal landscape

Chapter 4. Diagnostic Enzymes Market: Type Estimates & Trend Analysis

• 4.1. Segment Dashboard
• 4.2. Diagnostic Enzymes Market: Type Movement Analysis
• 4.3. Diagnostic Enzymes Market by Type Outlook (USD Million)
• 4.4. Market Size & Forecasts and Trend Analyses, 2018 to 2030 for the following
• 4.5. Taq Polymerase
  • 4.5.1. Taq Polymerase Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
• 4.6. MMLV RT
  • 4.6.1. MMLV RT Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
• 4.7. HIV RT
  • 4.7.1. HIV RT Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
• 4.8. Hot Start Taq Pol
  • 4.8.1. Hot Start Taq Pol Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
• 4.9. UNG
  • 4.9.1. UNG Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
• 4.10. Rnase Inhibitors
  • 4.10.1. Rnase Inhibitors Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
• 4.11. Bst Polymerase (LAMP ENZYME)
  • 4.11.1. Bst Polymerase (LAMP ENZYME) Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
• 4.12. PCR Master Mix
  • 4.12.1. PCR Master Mix Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
• 4.13. Lyophilized Polymerase
  • 4.13.1. Lyophilized Polymerase Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
• 4.14. T7 Rna Polymerase
  • 4.14.1. T7 Rna Polymerase Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
• 4.15. Cas9 Enzyme
  • 4.15.1. Cas9 Enzyme Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
• 4.16. Acid Phosphatase
  • 4.16.1. Acid Phosphatase Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
• 4.17. Alanine Aminotransferase
  • 4.17.1. Alanine Aminotransferase Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
• 4.18. Alkaline Phosphatase
  • 4.18.1. Alkaline Phosphatase Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
• 4.19. Amylase
  • 4.19.1. Amylase Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
• 4.20. Angiotensin Converting Enzyme
  • 4.20.1. Angiotensin Converting Enzyme Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
• 4.21. Aspartate Aminotransferase
  • 4.21.1. Aspartate Aminotransferase Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
• 4.22. Cholinesterase
  • 4.22.1. Cholinesterase Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
• 4.23. Creatinine Kinase
  • 4.23.1. Creatinine Kinase Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
• 4.24. Gamma Glutamyl Transferase
  • 4.24.1. Gamma Glutamyl Transferase Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
• 4.25. Lactate Dehydrogenase
  • 4.25.1. Lactate Dehydrogenase Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
• 4.26. Renin
  • 4.26.1. Renin Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
• 4.27. Glucose Oxidase/Glucose Dehydrogenase
  • 4.27.1. Glucose Oxidase/Glucose Dehydrogenase Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
• 4.28. Urease
  • 4.28.1. Urease Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
• 4.29. Lactate Oxidase
  • 4.29.1. Lactate Oxidase Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
• 4.30. Horseradish Peroxide
  • 4.30.1. Horseradish Peroxide Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
• 4.31. Glutamate Oxidase
  • 4.31.1. Glutamate Oxidase Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
• 4.32. Others
  • 4.32.1. Others Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)

Chapter 5. Diagnostic Enzymes Market: Application Estimates & Trend Analysis

• 5.1. Segment Dashboard
• 5.2. Diagnostic Enzymes Market: Application Movement Analysis
• 5.3. Diagnostic Enzymes Market by Application Outlook (USD Million)
• 5.4. Market Size & Forecasts and Trend Analyses, 2018 to 2030 for the following
• 5.5. Diabetes
  • 5.5.1. Diabetes Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
• 5.6. Oncology
  • 5.6.1. Oncology Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
• 5.7. Cardiology
  • 5.7.1. Cardiology Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
• 5.8. Infectious Disease
  • 5.8.1. Infectious Disease Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
• 5.9. Nephrology
  • 5.9.1. Nephrology Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
• 5.10. Autoimmune Diseases
  • 5.10.1. Autoimmune Diseases Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
• 5.11. Others
  • 5.11.1. Others Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)

Chapter 6. Diagnostic Enzymes Market: Product Estimates & Trend Analysis

• 6.1. Segment Dashboard
• 6.2. Diagnostic Enzymes Market: Product Movement Analysis
• 6.3. Diagnostic Enzymes Market by Product Outlook (USD Million)
• 6.4. Market Size & Forecasts and Trend Analyses, 2018 to 2030 for the following
• 6.5. Molecular Enzymes
  • 6.5.1. Molecular Enzymes Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
• 6.6. Clinical Enzymes
  • 6.6.1. Clinical Enzymes Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)

Chapter 7. Diagnostic Enzymes Market: End Use Estimates & Trend Analysis

• 7.1. Segment Dashboard
• 7.2. Diagnostic Enzymes Market: End Use Movement Analysis
• 7.3. Diagnostic Enzymes Market by End Use Outlook (USD Million)
• 7.4. Market Size & Forecasts and Trend Analyses, 2018 to 2030 for the following
• 7.5. Hospital
  • 7.5.1. Hospital Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
• 7.6. Clinical Laboratories
  • 7.6.1. Clinical Laboratories Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
• 7.7. Others
  • 7.7.1. Others Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)

Chapter 8. Diagnostic Enzymes Market: Regional Estimates & Trend Analysis

• 8.1. Regional Dashboard
• 8.2. Market Size, & Forecasts Trend Analysis, 2018 to 2030:
• 8.3. North America
  • 8.3.1. U.S.
    • 8.3.1.1. Key country dynamics
    • 8.3.1.2. Regulatory framework/ reimbursement structure
    • 8.3.1.3. Competitive scenario
    • 8.3.1.4. U.S. market estimates and forecasts 2018 to 2030 (USD Million)
  • 8.3.2. Canada
    • 8.3.2.1. Key country dynamics
    • 8.3.2.2. Regulatory framework/ reimbursement structure
    • 8.3.2.3. Competitive scenario
    • 8.3.2.4. Canada market estimates and forecasts 2018 to 2030 (USD Million)
  • 8.3.3. Mexico
    • 8.3.3.1. Key country dynamics
    • 8.3.3.2. Regulatory framework/ reimbursement structure
    • 8.3.3.3. Competitive scenario
    • 8.3.3.4. Mexico market estimates and forecasts 2018 to 2030 (USD Million)
• 8.4. Europe
  • 8.4.1. UK
    • 8.4.1.1. Key country dynamics
    • 8.4.1.2. Regulatory framework/ reimbursement structure
    • 8.4.1.3. Competitive scenario
    • 8.4.1.4. UK market estimates and forecasts 2018 to 2030 (USD Million)
  • 8.4.2. Germany
    • 8.4.2.1. Key country dynamics
    • 8.4.2.2. Regulatory framework/ reimbursement structure
    • 8.4.2.3. Competitive scenario
    • 8.4.2.4. Germany market estimates and forecasts 2018 to 2030 (USD Million)
  • 8.4.3. France
    • 8.4.3.1. Key country dynamics
    • 8.4.3.2. Regulatory framework/ reimbursement structure
    • 8.4.3.3. Competitive scenario
    • 8.4.3.4. France market estimates and forecasts 2018 to 2030 (USD Million)
  • 8.4.4. Italy
    • 8.4.4.1. Key country dynamics
    • 8.4.4.2. Regulatory framework/ reimbursement structure
    • 8.4.4.3. Competitive scenario
    • 8.4.4.4. Italy market estimates and forecasts 2018 to 2030 (USD Million)
  • 8.4.5. Spain
    • 8.4.5.1. Key country dynamics
    • 8.4.5.2. Regulatory framework/ reimbursement structure
    • 8.4.5.3. Competitive scenario
    • 8.4.5.4. Spain market estimates and forecasts 2018 to 2030 (USD Million)
  • 8.4.6. Norway
    • 8.4.6.1. Key country dynamics
    • 8.4.6.2. Regulatory framework/ reimbursement structure
    • 8.4.6.3. Competitive scenario
    • 8.4.6.4. Norway market estimates and forecasts 2018 to 2030 (USD Million)
  • 8.4.7. Sweden
    • 8.4.7.1. Key country dynamics
    • 8.4.7.2. Regulatory framework/ reimbursement structure
    • 8.4.7.3. Competitive scenario
    • 8.4.7.4. Sweden market estimates and forecasts 2018 to 2030 (USD Million)
  • 8.4.8. Denmark
    • 8.4.8.1. Key country dynamics
    • 8.4.8.2. Regulatory framework/ reimbursement structure
    • 8.4.8.3. Competitive scenario
    • 8.4.8.4. Denmark market estimates and forecasts 2018 to 2030 (USD Million)
• 8.5. Asia Pacific
  • 8.5.1. Japan
    • 8.5.1.1. Key country dynamics
    • 8.5.1.2. Regulatory framework/ reimbursement structure
    • 8.5.1.3. Competitive scenario
    • 8.5.1.4. Japan market estimates and forecasts 2018 to 2030 (USD Million)
  • 8.5.2. China
    • 8.5.2.1. Key country dynamics
    • 8.5.2.2. Regulatory framework/ reimbursement structure
    • 8.5.2.3. Competitive scenario
    • 8.5.2.4. China market estimates and forecasts 2018 to 2030 (USD Million)
  • 8.5.3. India
    • 8.5.3.1. Key country dynamics
    • 8.5.3.2. Regulatory framework/ reimbursement structure
    • 8.5.3.3. Competitive scenario
    • 8.5.3.4. India market estimates and forecasts 2018 to 2030 (USD Million)
  • 8.5.4. Australia
    • 8.5.4.1. Key country dynamics
    • 8.5.4.2. Regulatory framework/ reimbursement structure
    • 8.5.4.3. Competitive scenario
    • 8.5.4.4. Australia market estimates and forecasts 2018 to 2030 (USD Million)
  • 8.5.5. South Korea
    • 8.5.5.1. Key country dynamics
    • 8.5.5.2. Regulatory framework/ reimbursement structure
    • 8.5.5.3. Competitive scenario
    • 8.5.5.4. South Korea market estimates and forecasts 2018 to 2030 (USD Million)
  • 8.5.6. Thailand
    • 8.5.6.1. Key country dynamics
    • 8.5.6.2. Regulatory framework/ reimbursement structure
    • 8.5.6.3. Competitive scenario
    • 8.5.6.4. Thailand market estimates and forecasts 2018 to 2030 (USD Million)
• 8.6. Latin America
  • 8.6.1. Brazil
    • 8.6.1.1. Key country dynamics
    • 8.6.1.2. Regulatory framework/ reimbursement structure
    • 8.6.1.3. Competitive scenario
    • 8.6.1.4. Brazil market estimates and forecasts 2018 to 2030 (USD Million)
  • 8.6.2. Argentina
    • 8.6.2.1. Key country dynamics
    • 8.6.2.2. Regulatory framework/ reimbursement structure
    • 8.6.2.3. Competitive scenario
    • 8.6.2.4. Argentina market estimates and forecasts 2018 to 2030 (USD Million)
• 8.7. MEA
  • 8.7.1. South Africa
    • 8.7.1.1. Key country dynamics
    • 8.7.1.2. Regulatory framework/ reimbursement structure
    • 8.7.1.3. Competitive scenario
    • 8.7.1.4. South Africa market estimates and forecasts 2018 to 2030 (USD Million)
  • 8.7.2. Saudi Arabia
    • 8.7.2.1. Key country dynamics
    • 8.7.2.2. Regulatory framework/ reimbursement structure
    • 8.7.2.3. Competitive scenario
    • 8.7.2.4. Saudi Arabia market estimates and forecasts 2018 to 2030 (USD Million)
  • 8.7.3. UAE
    • 8.7.3.1. Key country dynamics
    • 8.7.3.2. Regulatory framework/ reimbursement structure
    • 8.7.3.3. Competitive scenario
    • 8.7.3.4. UAE market estimates and forecasts 2018 to 2030 (USD Million)
  • 8.7.4. Kuwait
    • 8.7.4.1. Key country dynamics
    • 8.7.4.2. Regulatory framework/ reimbursement structure
    • 8.7.4.3. Competitive scenario
    • 8.7.4.4. Kuwait market estimates and forecasts 2018 to 2030 (USD Million)

Chapter 9. Competitive Landscape

• 9.1. Market Participant Categorization
• 9.2. Recent Developments & Impact Analysis by Key Market Participants
• 9.3. Company Market Share Analysis, 2024
• 9.4. Key Company Profiles
  • 9.4.1. Takara Bio, Inc.
    • 9.4.1.1. Company overview
    • 9.4.1.2. Financial performance
    • 9.4.1.3. Product benchmarking
    • 9.4.1.4. Strategic initiatives
  • 9.4.2. Promega Corporation
    • 9.4.2.1. Company overview
    • 9.4.2.2. Financial performance
    • 9.4.2.3. Product benchmarking
    • 9.4.2.4. Strategic initiatives
  • 9.4.3. Enzo Biochem Inc
    • 9.4.3.1. Company overview
    • 9.4.3.2. Financial performance
    • 9.4.3.3. Product benchmarking
    • 9.4.3.4. Strategic initiatives
  • 9.4.4. Merck KGaA
    • 9.4.4.1. Company overview
    • 9.4.4.2. Financial performance
    • 9.4.4.3. Product benchmarking
    • 9.4.4.4. Strategic initiatives
  • 9.4.5. Thermo Fisher Scientific, Inc
    • 9.4.5.1. Company overview
    • 9.4.5.2. Financial performance
    • 9.4.5.3. Product benchmarking
    • 9.4.5.4. Strategic initiatives
  • 9.4.6. Creative Enzymes
    • 9.4.6.1. Company overview
    • 9.4.6.2. Financial performance
    • 9.4.6.3. Product benchmarking
    • 9.4.6.4. Strategic initiatives
  • 9.4.7. F. Hoffmann-La Roche Ltd.
    • 9.4.7.1. Company overview
    • 9.4.7.2. Financial performance
    • 9.4.7.3. Product benchmarking
    • 9.4.7.4. Strategic initiatives
  • 9.4.8. Solis BioDyne
    • 9.4.8.1. Company overview
    • 9.4.8.2. Financial performance
    • 9.4.8.3. Product benchmarking
    • 9.4.8.4. Strategic initiatives
  • 9.4.9. Ambliqon A/S.
    • 9.4.9.1. Company overview
    • 9.4.9.2. Financial performance
    • 9.4.9.3. Product benchmarking
    • 9.4.9.4. Strategic initiatives
  • 9.4.10. Yashraj Biotechnology Ltd.
    • 9.4.10.1. Company overview
    • 9.4.10.2. Financial performance
    • 9.4.10.3. Product benchmarking
    • 9.4.10.4. Strategic initiatives